Department of Dermatology and Venereology, Faculty of Medicine for girls, Al-Azhar University, Cairo, Egypt.
J Eur Acad Dermatol Venereol. 2013 Jun;27(6):686-93. doi: 10.1111/j.1468-3083.2012.04535.x. Epub 2012 Apr 6.
Treatment of female pattern hair loss (FPHL) is frustrating for both patients and doctors. Mesotherapy is a novel treatment for hair fall and its efficacy in FPHL has not been evaluated.
Evaluation of the efficacy and safety of mesotherapy using dutasteride-containing preparation in treatment of FPHL.
This study included 126 female patients with FPHL. They were classified into two groups; group I (86 patients) injected with dutasteride-containing preparation and group II (40 control patients) injected with saline. Patients received 12 sessions and were evaluated at the 18th week by: photographic assessment, hair pull test, hair diameter and patient self-assessment. Ultrastructural evaluation was done for three patients.
After mesotherapy with dutasteride-containing preparation, photographic improvement occurred in 62.8% of patients compared with 17.5% in control group (P < 0.05), mean number of epilated hairs was significantly decreased (P < 0.05), mean hair diameter was significantly increased (P < 0.05). Patient self-assessment showed statistically significant improvement compared with the controls (P < 0.05). There was a negative correlation between degree of improvement and duration of FPHL (P < 0.05). Side effects were minimal with no statistically significant difference between the two groups (P > 0.05). Ultrastructural examination of pretreated hairs revealed absent cuticle in one patient and focal destruction of the cuticle in the second patient, which reappeared in both after therapy.
We concluded that mesotherapy with dutasteride-containing preparation was effective, tolerable and minimally invasive treatment modality in FPHL with better response for shorter duration of the disease.
女性型脱发(FPHL)的治疗令医患双方都感到沮丧。中胚层疗法是一种治疗脱发的新方法,但尚未评估其在 FPHL 中的疗效。
评估含有度他雄胺的制剂进行中胚层疗法治疗 FPHL 的疗效和安全性。
本研究纳入了 126 例 FPHL 女性患者。将其分为两组;I 组(86 例)注射含有度他雄胺的制剂,II 组(40 例对照患者)注射生理盐水。患者接受 12 次治疗,并在第 18 周通过以下方式进行评估:摄影评估、毛发牵拉试验、毛发直径和患者自我评估。对 3 名患者进行超微结构评估。
与对照组(17.5%)相比,接受含有度他雄胺的制剂中胚层疗法后,62.8%的患者出现摄影改善(P<0.05),拔毛数量显著减少(P<0.05),毛发直径显著增加(P<0.05)。与对照组相比,患者自我评估显示有统计学意义的改善(P<0.05)。改善程度与 FPHL 的持续时间呈负相关(P<0.05)。两组之间的副作用最小,无统计学差异(P>0.05)。预处理毛发的超微结构检查显示,一名患者的表皮缺失,另一名患者的表皮局灶性破坏,治疗后两者均再次出现。
我们得出结论,含有度他雄胺的制剂中胚层疗法是一种有效、耐受和微创的治疗方法,对病程较短的 FPHL 反应更好。